Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Reported today (16 July 2018) in the journal Nature Biotechnology, the study also revealed that standard tests for detecting DNA changes miss finding this genetic damage, and that caution and specific testing will be required for any potential gene therapies.
CRISPR/Cas9 is one of the newest genome editing tools. It can alter sections of DNA in cells by cutting at specific points and introducing changes at that location. Already extensively used in scientific research, CRISPR/Cas9 has also been seen as a promising way to create potential genome editing treatments for diseases such as HIV, cancer or sickle cell disease. Such therapeutics could inactivate a disease-causing gene, or correct a genetic mutation. However, any potential treatments would have to prove that they were safe.
Previous research had not shown many unforeseen mutations from CRISPR/Cas9 in the DNA at the genome editing target site. To investigate this further the researchers carried out a full systematic study in both mouse and human cells and discovered that CRISPR/Cas9 frequently caused extensive mutations, but at a greater distance from the target site.
The researchers found many of the cells had large genetic rearrangements such as DNA deletions and insertions. These could lead to important genes being switched on or off, which could have major implications for CRISPR/Cas9 use in therapies. In addition, some of these changes were too far away from the target site to be seen with standard genotyping methods.
“This is the first systematic assessment of unexpected events resulting from CRISPR/Cas9 editing in therapeutically relevant cells, and we found that changes in the DNA have been seriously underestimated before now. It is important that anyone thinking of using this technology for gene therapy proceeds with caution, and looks very carefully to check for possible harmful effects.”
Professor Allan Bradley, corresponding author on the study from the Wellcome Sanger Institute
“My initial experiment used CRISPR/Cas9 as a tool to study gene activity, however it became clear that something unexpected was happening. Once we realised the extent of the genetic rearrangements we studied it systematically, looking at different genes and different therapeutically relevant cell lines, and showed that the CRISPR/Cas9 effects held true.”
Michael Kosicki, the first author from the Wellcome Sanger Institute
The work has implications for how CRISPR/Cas9 is used therapeutically and is likely to re-spark researchers’ interest in finding alternatives to the standard CRISPR/Cas9 method for gene editing.
“This study is the first to assess the repertoire of genomic damage arising at a CRISPR/Cas9 cleavage site. While it is not known if genomic sites in other cell lines will be affected in the same way, this study shows that further research and specific testing is needed before CRISPR/Cas9 is used clinically.”
Professor Maria Jasin, an independent researcher from Memorial Slone Kettering Cancer Centre, New York, who was not involved in the study
Receive an email update when we add a new CRISPR/Cas9 article.
The Latest on: CRISPR/Cas9
via Google News
The Latest on: CRISPR/Cas9
- C4XD, Horizon to develop synthetic lethality targets in oncology on December 17, 2018 at 11:09 pm
The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemist... […]
- CRISPR may restore effectiveness of chemotherapies used to treat lung cancer on December 17, 2018 at 10:28 pm
The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or "knocking out" a gene in cancer tumors that helps the ... […]
- Calyxt (CLXT) Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants on December 17, 2018 at 12:32 pm
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the issuan... […]
- Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants on December 17, 2018 at 12:30 pm
Calyxt, Inc. CLXT, +23.79% a consumer-centric, food- and agriculture-focused company, today announced the issuance of European patent No. 3008186, which claims methods to create gene-edited plants by ... […]
- Just Because We Can Create Genetically Modified Babies Doesn’t Mean We Should on December 17, 2018 at 12:18 pm
In turn, the Chinese government condemned the doctor and called for an immediate investigation. At issue is a developing biotechnology known as CRISPR-Cas9 that allows scientists to genetically edit c... […]
- Book Review: 'Pandemic' rings warning bell about gene-editing technology on December 16, 2018 at 8:27 am
In his latest medical thriller, "Pandemic," Cook dramatizes the scary side of a miracle molecule called "CRISPR/Cas9," which can easily be custom-tailored to seek out and alter genes in humans and ani... […]
- Scientists discover rules that determine precision of CRISPR/Cas9 genome editing in human cells on December 13, 2018 at 10:19 pm
Scientists at the Francis Crick Institute have discovered a set of simple rules that determine the precision of CRISPR/Cas9 genome editing in human cells. These rules, published in Molecular Cell, cou... […]
- ERS Genomics and Lonza Enter Into CRISPR/Cas9 Technology Licensing Deal on December 13, 2018 at 12:00 am
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the abi... […]
- MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models on December 10, 2018 at 8:38 am
- genOway to acquire exclusive rights to MilliporeSigma's foundational genome-editing patents to produce, sell rodent models - New technologies and solutions to be developed using CRISPR/Cas9 to ... […]
via Bing News